Suppr超能文献

通过 c-Abl 介导的酪氨酸磷酸化调控 parkin 功能:对帕金森病的影响。

Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.

机构信息

Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229, USA.

出版信息

J Neurosci. 2011 Jan 5;31(1):157-63. doi: 10.1523/JNEUROSCI.1833-10.2011.

Abstract

Mutations in parkin, an E3 ubiquitin ligase, are the most common cause of autosomal-recessive Parkinson's disease (PD). Here, we show that the stress-signaling non-receptor tyrosine kinase c-Abl links parkin to sporadic forms of PD via tyrosine phosphorylation. Under oxidative and dopaminergic stress, c-Abl was activated in cultured neuronal cells and in striatum of adult C57BL/6 mice. Activated c-Abl was found in the striatum of PD patients. Concomitantly, parkin was tyrosine-phosphorylated, causing loss of its ubiquitin ligase and cytoprotective activities, and the accumulation of parkin substrates, AIMP2 (aminoacyl tRNA synthetase complex-interacting multifunctional protein 2) (p38/JTV-1) and FBP-1.STI-571, a selective c-Abl inhibitor, prevented tyrosine phosphorylation of parkin and restored its E3 ligase activity and cytoprotective function both in vitro and in vivo. Our results suggest that tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that leads to loss of parkin function and disease progression in sporadic PD. Moreover, inhibition of c-Abl offers new therapeutic opportunities for blocking PD progression.

摘要

Parkin 是一种 E3 泛素连接酶,其突变是常染色体隐性遗传帕金森病(PD)最常见的原因。在这里,我们发现应激信号非受体酪氨酸激酶 c-Abl 通过酪氨酸磷酸化将 parkin 与散发性 PD 联系起来。在氧化和多巴胺能应激下,c-Abl 在培养的神经元细胞和成年 C57BL/6 小鼠的纹状体中被激活。PD 患者的纹状体中发现了活化的 c-Abl。同时,parkin 发生酪氨酸磷酸化,导致其失去泛素连接酶和细胞保护活性,并积累 parkin 底物,AIMP2(氨基酰 tRNA 合成酶复合物相互作用多功能蛋白 2)(p38/JTV-1)和 FBP-1。STI-571 是一种选择性 c-Abl 抑制剂,可防止 parkin 的酪氨酸磷酸化,并在体外和体内恢复其 E3 连接酶活性和细胞保护功能。我们的研究结果表明,c-Abl 对 parkin 的酪氨酸磷酸化是导致散发性 PD 中 parkin 功能丧失和疾病进展的主要翻译后修饰。此外,抑制 c-Abl 为阻止 PD 进展提供了新的治疗机会。

相似文献

2
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. doi: 10.1073/pnas.1006083107. Epub 2010 Sep 7.
3
Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
PLoS One. 2013 May 31;8(5):e65129. doi: 10.1371/journal.pone.0065129. Print 2013.
5
Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.
J Neuropathol Exp Neurol. 2011 Aug;70(8):686-97. doi: 10.1097/NEN.0b013e3182269ecd.
6
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1202-7. doi: 10.1073/pnas.1417423112. Epub 2015 Jan 12.
7
Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity.
J Neurochem. 2015 Aug;134(4):756-68. doi: 10.1111/jnc.13164. Epub 2015 Jun 3.
9
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.
Brain. 2021 Dec 31;144(12):3674-3691. doi: 10.1093/brain/awab356.

引用本文的文献

1
Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation.
NPJ Parkinsons Dis. 2025 Aug 26;11(1):261. doi: 10.1038/s41531-025-01084-y.
3
c-Abl Inhibitors in Parkinson's: Exploring Hypotheses on Alpha-Synuclein Modulation.
Adv Pharm Bull. 2025 Feb 9;15(1):7-10. doi: 10.34172/apb.42806. eCollection 2025 Apr.
4
Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons.
NPJ Parkinsons Dis. 2025 Jun 21;11(1):180. doi: 10.1038/s41531-025-01038-4.
5
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.
Mol Neurodegener. 2025 May 8;20(1):53. doi: 10.1186/s13024-025-00839-8.
6
Neuroprotective role and mechanistic insights of DJ-1 dimerization in Parkinson's disease.
Cell Commun Signal. 2025 Mar 10;23(1):129. doi: 10.1186/s12964-025-02136-9.
9
α-Synuclein pathology as a target in neurodegenerative diseases.
Nat Rev Neurol. 2025 Jan;21(1):32-47. doi: 10.1038/s41582-024-01043-w. Epub 2024 Nov 28.
10
AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson's disease.
J Transl Med. 2024 Oct 10;22(1):919. doi: 10.1186/s12967-024-05666-x.

本文引用的文献

2
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
J Biol Chem. 2006 Jun 16;281(24):16193-6. doi: 10.1074/jbc.C600041200. Epub 2006 May 3.
3
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro.
J Biol Chem. 2006 Feb 10;281(6):3204-9. doi: 10.1074/jbc.M510393200. Epub 2005 Dec 8.
4
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.
Hum Mol Genet. 2005 Dec 15;14(24):3885-97. doi: 10.1093/hmg/ddi413. Epub 2005 Nov 8.
5
Dopamine covalently modifies and functionally inactivates parkin.
Nat Med. 2005 Nov;11(11):1214-21. doi: 10.1038/nm1314. Epub 2005 Oct 16.
8
Molecular pathophysiology of Parkinson's disease.
Annu Rev Neurosci. 2005;28:57-87. doi: 10.1146/annurev.neuro.28.061604.135718.
10
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity.
J Biol Chem. 2005 Feb 4;280(5):3390-9. doi: 10.1074/jbc.M407724200. Epub 2004 Nov 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验